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ABSTRACT 
Rheumatoid arthritis (RA) is a systemic autoimmune joint disease, in which 
chronic inflammation and hyperplastic synovial tissue mediates destruction 
of cartilage and bone. Survivin is known as an intracellular inhibitor of 
apoptosis and a positive regulator of cell division. Previous studies have 
shown that extracellular survivin can be detected in blood and synovial fluid 
from patients diagnosed with RA and that survivin in blood can predict 
destructive course of arthritis and poor response to anti-rheumatic treatment. 
The role of survivin in arthritis, the cellular source and processes leading to 
the release of survivin are far from understood. Two proteins, the  
differentiation factor Fms-like tyrosine kinase 3 ligand (Flt3L) and the 
Urokinase plasminogen activator (uPA) were positively associated to 
survivin in rheumatoid arthritis patients. The aim of this thesis was to 
investigate the role of Flt3 signalling for survivin production for arthritis 
development using the mBSA arthritis model and the role of survivin and 
urokinase signalling for the arthritogenic properties of synovial fibroblasts.  
Intracellular survivin expression was evaluated in the mBSA arthritis model 
after Flt3 activation with Flt3L or inhibition using or an Flt3 inhibitor, 
sunitinib. Changes in the frequencies of immune cell populations and the 
effect on arthritis development were evaluated after Flt3 inhibition. In 
addition, RNA silencing was used to directly target survivin in in vitro and in 
a human/SCID chimera model to study the impact of survivin on the 
arthritogenic properties of fibroblasts. 
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 The results presented in this thesis show that survivin is expressed in bone 
marrow and DCs in response to activation of the receptor tyrosine kinase Flt3 
in vivo. Inhibition of Flt3 reduces survivin production, dendritic cell 
formation and synovial inflammation. uPA release from fibroblasts is 
survivin dependent and silencing of survivin in human fibroblasts reduced 
cartilage destruction in the knee joints of SCID mice. In conclusion, survivin 
may enhance the survival of antigen presenting dendritic cells and the 
arthritogenic properties of synovial fibroblasts in the RA joint. 
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SAMMANFATTNING PÅ SVENSKA 
Ledgångsreumatism (reumatoid artrit) är en sjukdom som drabbar ca 1% av 
befolkningen. Det är en autoimmun sjukdom där kroppens eget 
immunförsvar angriper vävnaden i lederna, som om den vore främmande. 
Den kroniska inflammationen leder till nedbrytning av brosk och 
benförstörelse, vilket medför kraftigt nedsatt funktion. Möjligheterna att 
diagnostisera och bromsa förloppet av sjukdomen har förbättrats avsevärt på 
senare år, men det finns än idag inget botemedel och det behövs bättre 
markörer för att tidigt identifiera patienter med särskilt snabbt förlopp.  
Survivin är ett protein som är viktigt för att celler ska kunna dela sig och för 
att förhindra programmerad celldöd. I cancer är nivåerna av survivin särskilt 
höga, vilket leder till överlevnad av cancercellerna. Vi har i tidigare studier 
visat att höga nivåer av survivin även finns lösligt i blodet och ledvätskan hos 
vissa patienter med reumatoid artrit och att de oftare drabbas av 
leddestruktioner än andra patienter. I patientgruppen med högt survivin fanns 
det två andra proteiner, Flt3-ligand och urokinas, som också förekom i högre 
nivåer än hos andra patienter. I denna avhandling har vi försökt koppla 
survivinet till cellulära processer som kan förklara denna förekomst, samt 
undersöka om de har betydelse för utveckling av artrit. 
Flt3-ligand främjar stamcellers utveckling till dendritiska celler, vilka har till 
uppgift att visa upp främmande proteiner för T cellerna och aktivera dessa, så 
att den specifika delen av immunförsvaret (den adaptiva) kan rikta sitt svar 
mot angripare som bakterier, virus och parasiter. Vi provade att behandla 
möss med artrit, dels med injektioner av Flt3-ligand och dels med en 
inhibitor (sunitinib), som hämmar den receptor som Flt3-liganden binder till. 
Vi såg att Flt3-ligand ledde till högre nivåer och sunitinib till lägre nivåer av 
survivin inuti de dendritiska cellerna. Sunitinib-behandlingen ledde dessutom 
till mildare artrit, vilket vi tror berodde på att de hade färre dendritiska celler 
som kunde aktivera immunförvaret att angripa leden. 
Urokinas är ett protein som kan bryta ner det extracellulära matrix som 
omger celler. Vi såg att bindvävsceller som kom ifrån lederna ifrån patienter 
(synoviala fibroblaster), frisätter urokinas. De hade även höga nivåer survivin 
och vi kunde hindra urokinas-frisättningen genom med hjälp av RNA 
interferens, blockera survivin-syntesen i fibroblasterna. Om vi satte in 
fibroblaster i en mus-led, ledde detta till en kraftig artrit men inte om vi 
blockerade survivin-syntesen först. Urokinas kan också binda till en receptor, 
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blockerade survivin-syntesen först. Urokinas kan också binda till en receptor, 
 och om vi stimulerade celler som hade denna receptor kunde vi se att 
survivin-nivåerna ökade i de cellerna. 
Vi har således visat att survivin finns i både dendritiska celler och synoviala 
fibroblaster och att nivåerna kan öka då nivåerna av Flt3L och urokinas ökar. 
Survivin kan i sin tur öka frisättning av urokinas och Flt3L. Man kan bromsa 
denna process genom RNA interferens mot survivin eller genom att blockera 
Flt3-ligand signaleringen. Denna ökade kunskap om reglering av survivin-
produktion och survivinets effekter kan på sikt öppna för nya 
behandlingsmöjligheter för patienter med reumatoid artrit.  
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1 INTRODUCTION 
Rheumatoid arthritis (RA) is a chronic autoimmune disease that leads to 
inflammation in the synovium in addition to cartilage and bone destruction. 
The synovial tissue consists mainly of fibroblasts and during RA, these cells 
become activated and gain tumour-like features such as expansive growth, 
increased migratory functions [1] and resistance to apoptosis [2]. Further, 
during the rheumatic inflammation, peripheral leukocytes such as T cells, B 
cells, dendritic cells (DCs), macrophages and neutrophils invade the 
synovium. Despite extensive research and development of effective 
therapeutics, interplay between these different cell types are far from 
understood [3]. Thus the aim of this thesis was to investigate the importance 
of Flt3L and uPA signalling on survivin expression in experimental arthritis 
in order to a) further understand the pathogenesis behind arthritis 
development and b) investigate new biomarkers and new possible treatments 
for RA patients. 
1.1 Hypothesis 
We hypothesised that tyrosine kinase signalling induce survivin, which leads 
to accumulation of survivin in leukocytes and synovial fibroblasts and 
subsequent survival of autoreactive cells in RA. 
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2 RHEUMATOID ARTHRITIS 
Rheumatoid arthritis is a systemic autoimmune joint disease, in which 
chronic inflammation and hyperplastic synovial pannus tissue mediates 
destruction of cartilage and bone. The disease is one of the most common 
autoimmune diseases as it affects approximately 1% of the population with 
some regional variations. 
2.1 Autoimmunity and RA 
The immune system has evolved to protect us against infections without 
causing harm to the host, and must therefore be able to distinguish between 
self and non-self. The ability of the immune system to ignore endogenous 
structures is called tolerance and is maintained by an intricate network of 
immunological mechanisms. In autoimmune diseases the tolerance to self-
antigens is lost, and the immune system drives a chronic perpetual 
inflammation that is triggered by endogenous antigens.  
Tolerance is maintained by exposure of self-antigens to lymphocytes and 
subsequent deletion, inactivation or changed function of autoreactive clones. 
This may occur during development (central tolerance), or in mature 
lymphocytes in the periphery (peripheral tolerance). Peripheral tolerance is 
essential to prevent autoreactivity also towards modified antigens and non-
self antigens when they do not cause harm. However, tolerance mechanisms 
can fail if there is a trigger that signals danger.  
Joint inflammation is a hallmark of RA and it is therefore natural to assume 
that the self-antigen originates from the joint. This could be an intra-articular 
cartilage component but it could also be an antigen that homes to the joint 
and binds to joint structures due to charge-mediated binding. Since the 
antigen remains in the joint and unlike the situation of infection cannot be 
cleared, chronic inflammation also characterises RA. Today, neither the 
initiating cause of disease nor the eliciting antigen is known. Similarity 
between a bacterial component and a self-antigen (molecular mimicry), or 
posttranslational modifications of self-antigens, which might occur during 
infections or tissue injury, are mechanisms that are commonly believed to 
cause break of tolerance and cause autoimmunity. 
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2.2 Aetiology 
Although the exact cause of RA remains elusive, we know that genetic 
disposition, gender, as well as environmental factors contribute to disease 
development. There are no strong associations to a single gene, but the 
concordance rate (around 15%) for monozygotic twins is considerably higher 
than in the general population [4]. The genetic variability that are most 
strongly associated to RA are linked to functions of the immune system 
including the genes for MHC II and PTPN22. Allelic variants of the HLA-
DRB1 in the MHC II locus (“shared epitope”) is around 4-5 times higher in 
RA patients compared to the general population [5]. A single nucleotide 
polymorphism in the PTPN22 gene encoding for a tyrosine phosphatase 
negatively regulating immune responses in T cells is associated with 
autoimmunity and RA [6]. Females have around three times higher risk of 
developing RA compared to males. 
Environmental triggers associated to development of RA are smoking [7] and 
silica dust [8], mineral oil [9] and infections [10-13].  
2.3 Autoantibodies 
2.3.1 Rheumatoid factor antibodies (RF) 
Rheumatoid factors (RF) are antibodies of any isotype, with specificity for 
the Fc-portion of IgG antibodies. RF form immune complexes with IgG and 
if injected into a joint they cause inflammation [14]. 70% of RA patients are 
positive for RF. The increase in RF at disease onset is used as a biomarker to 
distinguish patients with more severe clinical disease that are in need for 
active treatment. RF antibodies were considered to be the first evidence that 
the immune response in RA is directed towards self-antigens. However, 
although characteristic for RA, the specificity and sensitivity of RF for RA 
are 90% and 78% respectively, which means that these autoantibodies also 
are also present in other conditions and not an optimal biomarker for the 
disease.  
2.3.2 Anti-Citrullinated Protein Antibodies (ACPA)  
The specificity and sensitivity of ACPAs for RA is 95% and 60-70% 
respectively and therefore constitute a better biomarker for RA than RF. The 
assay commonly used to detect anti-citrullinated protein antibodies is the 
anti-cyclic citrullinated peptide (aCCP) assay, which has become a widely 
used diagnostic tool for RA [15]. Citrullination is the process by which the 
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amino acid arginine is converted to a citrulline. The reaction is catalysed by 
peptidyl arginine deaminases (PADs). One possible biological function of 
citrullination is to degrade intracellular proteins during apoptosis and it seems 
likely that this process is enhanced during inflammation [16] . Arginine is a 
positively charged while the citrulline is neutral, which leads to 
conformational changes of the protein and subsequent exposure of normally 
hidden antigens. Citrullination of some proteins that are expressed within the 
joint are of particular interest: α-enolase vimentin, filaggrin, fibrin/fibrinogen 
and collagen type II [17].  
Many parallel findings in patients with RA resulted in the discovery of 
citrullinated proteins as antigens and the anti-citrullinated protein antibodies 
(ACPA). In the 1970s the anti-keratin antibodies were found. They were 
called so because they bound to the squamous epithelium of rat esophagus, 
even though it was never clear if the keratin was the antigen. This was later 
shown not to be the case; instead the anti-keratin antibodies recognised 
epitopes on the citrullinated filaggrin [18] The anti-Sa antibodies was 
discovered in serum from a patient with rheumatoid arthritis whose name 
began with Sa, showed specificity for an antigen present in extracts from 
normal human placenta and spleen and was a poorly soluble protein around 
50kD [19] that was later identified as mutated and citrullinated vimentin [20]. 
The shared epitope predispose RA patients for development of ACPAs [21] 
and can be explained by the fact that high affinity binding of peptides to the 
shared epitope MHC II molecule is facilitated by citrullination of the peptide 
[22]. ACPAs are also present in serum the from healthy individuals, but 
predict subsequent onset of RA [15,23]  
2.4 Disease pathogenesis in RA 
In RA the synovial tissue becomes hyperplastic with proliferation and 
activation of synovial fibroblasts (FLS). There are also inflammatory 
infiltrates in this tissue that includes cells from the adaptive immune response 
like DCs, T and B-lymphocytes, which is a sign of chronic inflammation.  
DCs are efficient antigen presenters as they take up the autoantigen and 
present the antigen peptides in lymphoid organs (spleen and lymph nodes) 
and provide co-stimulation and cytokines that activate T cells and thereby 
initiate the adaptive immune response.  
Ectopic lymphoid structures are often found in the rheumatoid synovium. In 
these local foci antigens are presented, which result in activation of T and B 
cells and the production of cytokines and antibodies. T cells function as 
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enhancers of the innate immune system, by the production of cytokines like 
IFNγ and IL-17 that activates macrophages and mediate recruitment of 
inflammatory cells. Activated macrophages show enhanced phagocytosis and 
are producers of proinflammatory cytokines like TNFα and IL1β. RA-FLS 
secrete inflammatory mediators like PGE2, cytokines like IL-6 and IL-18 and 
chemokines like IL-8, MCP-1 and CXCL10 and proteolytic enzymes 
(proteases). There are increased levels of RANKL in the inflamed tissue that 
contributes to osteoclastogenesis. Autoantibodies form immune complexes 
that activate phagocytes via Fcγ receptors, which enhance antigen 
presentation and mediate the release of proteases. 
Cartilage degradation is performed mainly by soluble proteases such as 
matrix metalloproteinases (MMPs), serine proteases and cathepsins. The only 
cell type that can degrade mineralised bone is the osteoclast and they are 
formed within the joint during arthritis[24]  
 
 
Figure 1. RA pathogenesis. Innate sensing activates DCs that migrate to 
lymphoid organs to present antigens and activate T cells, which in turn activate B 
cells. Lymphocytes migrate back to the synovium where adaptive immunity is 
enhanced by autoantigens. Cytokines, chemokines and antibody immune 
complexes activate FLS. MΦ, Mast cells and neutrophils to release proteolytic 
enzymes that destroy cartilage and OC differentiated from MΦ erode bone. 
FLS=Fibroblast -like synoviocyte, MΦ =macrophage, OC=osteoclast 
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2.5 The synovial fibroblasts in RA 
The lining layer of the synovia in healthy joint is about 1-2 cell layer thick 
but is increased to about 10-15 layers in RA. It consists of Type A cells, that 
are macrophage-like synoviocytes (MLS) and type B cells, which are 
fibroblasts-like synoviocytes (FLS). In humans these cells can be separated 
by the expression of CD68 on MLS and CD90 and CD29 on FLS [25]. RA-
FLS become immunologically active, since they express MHC II which 
makes them capable of presenting antigens to T cells [26]. RA-FLS express 
the CCL19 and CCL21 - chemokines that attract the CCR7+ mature DCs and 
naïve T cells to the lymph node where antigen presentation and T cell 
activation occur [27]. RA-FLS are transformed in such a way that they retain 
their phenotype outside the joint, so they can act independently of 
inflammation and stimuli from inflammatory cells, which has been shown by 
implants in SCID mice. These implants cause damage to mouse cartilage [28] 
or human cartilage implants [29] without continuous activation by the 
immune system. RA-FLS implanted into SCID mouse was even seen to 
spread between distant implanted pieces of cartilage [30], which is an 
example of their enhanced migratory ability.  
2.5.1 Proliferation and defective apoptosis in RA  
Cells of the synovial lining acquire a phenotype resembling epithelial 
mesenchymal transition, which is a state where the cells loose attachment to 
the basement membrane and gain enhanced migratory, proliferative and 
tissue remodelling capacity and enhanced production of components of the 
extracellular matrix. The state is normal during embryogenesis and wound 
healing but is also adapted in cancer progression [31]. In RA-synoviocytes 
this is exemplified by the increased expression of α-smooth muscle actin, 
cadherin-11 [25], increased expression of vimentin [30], S100A4 [32] [33], 
and secretion of extracellular matrix degrading proteases (paper III) [30]. 
RA-FLS can acquire somatic mutations such as in tumour suppressor p53 
[34] and a gain of function mutation in a RAF-protein in the MAP kinase 
pathway [35], and they acquire epigenetic changes such as differentially 
hypomethylated loci [36] and activation of proto-oncogenes (paper III). RA-
FLS themselves secrete growth factor like such as PDGF, TGFβ and GM-
CSF in addition to angiogenic factors like VEGF that contribute to continued 
growth and transition [37]. 
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In line with these changes, RA-FLS do not only display an enhanced 
proliferation, but also reduced apoptosis, which is retained also when 
cultured in vitro [38]. Apoptosis, or programmed cell death, is essential for 
safe removal of damaged or autoreactive cells without provoking an immune 
response, since danger associated molecular patterns (DAMPs) that are 
potent activators of innate immunity are hidden in the apoptosome. [39]. 
Apoptosis can be triggered through the intrinsic pathways by factors such as 
like cellular stress and DNA damage or the extrinsic pathway through death 
receptors such as TRAIL receptors or Fas, which contribute to elimination of 
aberrant immune responses. [40]  
2.6 Receptor tyrosine kinases and RA 
Many of the growth factors present in high amounts in the rheumatic joint are 
ligands for receptor tyrosine kinases (RTK) (Figure 2). Tyrosine kinase 
phosphorylation is a mechanism involved in many cellular processes and 
signal transduction pathways controlling cell growth, survival, differentiation 
and angiogenesis [41]. Indeed, tyrosine residues in the RA synovium are 
heavily phosphorylated [42]. The RTKs are membrane-spanning receptors 
that receive extracellular signals through binding of a ligand and transmit the 
signal through tyrosine kinase phosphorylation (Figure 2). Binding of the 
RTK ligand induces dimerization, which induces a conformational change 
that makes the tyrosine kinase residues on the intracellular domain able to 
Figure 2. A) RTK and their ligands in the RA joint. B) Dimerization of the 
receptor induces auto-phosphorylation of the tyrosine residues. An adaptor 
protein becomes phosphorylated by the tyrosine residues and contains binding 
sites for downstream signalling proteins. 
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become auto-phosphorylated by ATP and then able to transfer that group to 
the adaptor protein. RTK activation leads to several cellular responses 
depending on the cell type, the proteins expressed and other received signals, 
as the tyrosine groups of the cytoplasmic tail can phosphorylate several 
different proteins and initiate various intracellular signalling cascades. Most 
well studied is the MAP kinase cascade and the PI3 kinase pathway [43] 
2.7 Experimental models of RA 
There are several models of RA in rodents that are used to study pathogenic 
mechanisms and evaluate new potential therapeutics.   
In induced arthritis models adjuvants are used in combination with an antigen 
to generate an immune response towards this particular antigen. In the 
mBSA-induced arthritis, the antigen is introduced directly into the joint after 
immunisation, which initiate a monoarthritis (paper I, paper II). The mBSA 
model is discussed in more detail below. As mentioned, humanised models 
like the transplantational human/SCID chimera mice (paper III) [44] can give 
information about the arthritogenic behaviour of transformed cells like 
isolated synovial fibroblast [29] acting in vivo, independently of T cells.  
In the collagen-induced arthritis model, adjuvant together with chicken or rat 
collagen causes a break of tolerance to mouse collagen type II, the major 
protein of the cartilage, which causes a destructive polyarthritis [45]. 
Injections with CII antibodies are sufficient to induce arthritis in the collagen-
antibody-induced arthritis model [46].  
2.7.1 mBSA arthritis 
The major principle of the antigen-induced arthritis model is injection of the 
antigen into a joint of a previously immunised animal. This induces a strong 
T cell mediated delayed-type hypersensitivity reaction locally. It can be 
induced in several species like rabbits, rats, guinea pigs and mice [47], the 
latter being the species used in this thesis (Paper I-II). The mBSA induced 
arthritis model has been widely used since it was noticed that mBSA has 
cationic properties that allows it to bind to the anionic surfaces in the joint 
cavity [48]. This results in chronic arthritis because of antigen retention in the 
joint [49]. Methylation of BSA will yield a BSA with a pI around 8.5, 
compared to native BSA that has a pI at 4.5. [47]  
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The advantages of the model as a model of RA are:  
 Simple –fast and with a well defined time of onset 
 It does not require any genetic susceptibility and can therefore be 
induced into any strain including various knockouts and transgenic 
animals. 
 Animal friendly - since it is a monoarthritis and does not severely 
affect the normal behavioural activities  
 Comparison with a normal joint in the same animal 
 Control of the severity by the amount of antigen injected locally. 
The model is well suited for studies regarding mechanisms of joint 
destruction following chronic arthritis [47]. It also holds a similarity to RA, 
since flares can be induced by local or systemic rechallenge with mBSA 
[50,51], but it is less well suited to study mechanisms of autoimmunity. One 
thing to consider when using this model is the cross-reaction towards native 
BSA as many recombinant proteins can contain traces of BSA, which can 
also cause immune reactions. A DTH reaction in the ear of a mBSA 
immunised animal could be achieved by native BSA causing a swelling to 
approximately 1/3 of the swelling caused by mBSA [49] 
2.7.2 Immunisation 
Mice are immunised at day 0 and boosted at day 7 before arthritis induction 
at day 21 (Paper I-II). An adjuvant is required to get an immune response 
towards the mBSA and will enable activation of the pattern recognition 
receptors (PRRs) so that the DCs will mature and provide co-stimulation to 
activate T lymphocytes. (Figure 3) The nature of an adaptive immune 
response is dependent on both the adjuvant and the antigen. The Freunds 
adjuvant supplemented with mycobacteria (complete Freunds adjuvant, CFA) 
was used to immunise the mice with mBSA (Paper I-II). Freunds adjuvant is 
a water-in-oil emulsion containing paraffin oil and a surfactant, which on its 
own is capable of inducing a Th1/Th2 immune response with antibody 
production by a mechanism that is not completely understood but may 
involve PRR stimulation at the injection site due to cellular damage [52]. For 
further polarisation of T cells into a Th1/ Th17 response, mycobacteria are 
added. They contain ligands for TLR 2, 4 and 9 [52], peptidoglycans that 
stimulate NOD receptors [53] and molecules recognised by CARD9 
dependent C-type lectin receptors [54]. It also seems to be that the mBSA 
antigen itself has immunogenic properties and can activate inflammasome-
mediated release of IL1-beta [55]. MyD88-dependent IL1-beta signalling is 
essential for Th17 polarisation [54]. Also, IL-6 has been shown to be crucial 
for the development of mBSA arthritis [56] 
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Figure 3. The mBSA arthritis model. A) Immunisation with complete Freunds 
adjuvant with mBSA activates PRRs on the dendritic cell that takes up the 
antigen for presentation on MHCII. DCs undergo maturation and increase their 
expression of MHCII, costimulatory molecules like B7, lymph node homing 
receptors like CCR7 and cytokines such as IL-12, IL, 23 and IL-6. In the lymph 
node the dendritic cell present antigen to T lymphocytes and provide 
costimulation to naive T cells recognizing the MHC with peptide. Activated T 
cells undergo clonal expansion and differentiate into effector T helper cells. They 
can then activate B cells to produce antibodies. B) Arthritis is induced by a knee 
injection with mBSA. Antigen retention is enabled by the positive charge of the 
mBSA molecule. Antigen presenting cells phagocyte mBSA and present it to 
effector T lymphocytes, which secrete cytokines like IFNγ and IL-17. Activated 
macrophages produce TNFα, IL-1 and IL-6. FLS produce IL-8 that recruits 
neutrophils, enzymes that target cartilage and RANKL that leads to osteoclast 
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2.7.3 Adaptive immune response with cells infiltrating the 
synovium 
The inflammation caused by the mBSA knee injection, with joint swelling is 
most prominent after about 3 days. After 7 days the swelling declines but this 
time-point is more optimal to measure the histopathological changes in 
cartilage and bone metabolism [47]. The synovitis can then be histologically 
evaluated after H&E staining of sections according to a 0-3 scale for the 
degree of synovitis (synovial hypertrophy and accumulation of inflammatory 
cells) where 1: mild, 2: moderate, 3: severe synovitis (Figure 15, Paper II). 
The presence of the bone and cartilage damage can also be histologically 
evaluated using H&E stain (Figure 4).  
The synovial infiltrate in the mBSA joint consists of both lymphocytes, 
neutrophils, plasma cells and mast cells [57]. mBSA arthritis is a T cell 
driven model and CD4+ T cells are most essential for arthritis development. 
The RAG-/- mouse lacking B and T cells are completely resistant [58]. 
Further investigations of the model have shown that it absolutely dependent 
on CD4+ T cells while the presence of CD8+ T cells are of less importance 
[58-61]. Adoptive transfer of T cells and DCs from an mBSA immunized 
mouse 11 days prior to the knee injection was sufficient to induce arthritis in 
naïve mice, while the transfer of T cells alone was not, which shows that 
Figure 4. Synovitis and erosions in the knee joint of different severity 7 
days after knee injection of mBSA, evaluated by histology. Knees are 
scored as: 0: no synovitis, 1: mild, 2: moderate, 3: severe synovitis.      
J= joint cavity. C= cartilage, Sy=synovitis, M=medulla, E=erosions 
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arthritis induced following injection by antigen specific T cells are further 
enhanced by supplementary injection of antigen presenting cells [62]. 
B cells and antibodies seem to be of minor importance for development of 
synovitis in mBSA arthritis. The µMT/µMT mice lacking B cells and IgM 
and IgG antibodies developed arthritis without any significant changes 
compared to the wildtype controls [58,59]. Spleen cell devoided of B cell by 
passage through a anti-immunoglobulin column could transfer susceptibility 
to arthritis similarly to transfer of total spleen cells [60]. Serum transfer could 
predispose mice to arthritis induction with cellular infiltration after knee 
injected mBSA, but to a very limited extent [60]. Interestingly, activating Fcγ 
receptors seem to be of importance for cartilage and bone degradation. IgG 
antibodies binds to FcγRI and FcγRIII on macrophages leading to 
macrophage activation [63], and to FcγRIV expressed on osteoclast 
precursors, promoting osteoclastogenesis [64]. Knockout of the activating Fc-
gamma receptors reduced cartilage destruction independently of 
inflammation [65], which suggests that mBSA antibodies are enhancers of 
damage to cartilage and bone in the mBSA arthritis model. Histological 
sections of the joint after arthritis induction with radiolabelled mBSA show 
that some of the mBSA sticks at the cartilage surface together with IgG and 
complement, indicating that immune complexes are formed. [48]. 
After mBSA injection activated TH1 and TH17 T cells infiltrate the synovium 
secreting IFNγ and IL-17. IL-17 has been shown to have a pronounced 
influence on the mBSA mediated response [66] and neutrophil recruitment to 
the joint [67], which are one of the early effects of arthritis induction [61]. B 
cells and macrophages will accumulate with time, which indicate that 
antibodies and activation of Fc gamma receptor on synovial macrophages 
will occur after some days [61]. The cellular infiltrate is more granulocyte 
rich in Balb/c mice than in C57Bl/6 [47], which suggests that different mouse 
strains may respond slightly different.  
Osteoclasts mediate bone destruction and target bone through release of 
enzymes like MMPs and Cathepsin K, while bound to the bone surface by 
integrin alphaVbeta3. The release of RANKL within the joint will lead to 
recruitment and osteoclast formation of the cells expressing RANK, which 
are mainly monocytes stimulated by M-CSF [24]. Arthritis induction by 
mBSA is followed by increased expression of RANKL in the synovia of the 
arthritic joint compared to the collateral joint [68]. The C-telopeptide of type 
I collagen (CTX-1) is a degradation product from Collagen type I (the major 
protein component in bone) which can be detected in the serum, when bone is 
degraded by osteoclasts [69](Paper II). 
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3 FUNCTIONS OF SURVIVIN IN CANCER 
AND AUTOIMMUNITY 
Survivin, (API4, TIAP) is the smallest inhibitor of apoptosis protein (IAP) 
with its 142 amino acids. It is a multifunctional protein, most extensively 
studied in the cancer field, where it has been implicated in cell proliferation, 
inhibition of apoptosis and angiogenesis [70]. Survivin is encoded by the 
Birc5 gene at chromosome 17q25 in the human, has a basal isoelectric point 
at 5.66, and exhibit important intracellular functions [71]. Furthermore, 
survivin has also been found in the extracellular space, however the source 
and function is at present not well known [72-74]. The function of survivin in 
different biological processes will be described below. 
3.1.1 Is survivin a cancer gene? 
Ambrosini et al first described survivin as a gene essential during fetal 
development and absent in terminally differentiated tissues, but re-expressed 
in cancers [75]. Survivin was then identified as 1 out of 40 differentially 
expressed genes in a large study using serial analysis of gene expression, in 
which around 3.5-million transcripts from different human cancer tissue 
(colon cancer, brain cancer, breast cancer, lung cancer, melanoma) was 
compared to terminally differentiated healthy tissue [76]. Expression of 
survivin in malignancies is associated with unfavourable outcome [77,78] 
and resistance to cytostatic treatment [79-81] Survivin is used as a tumor 
biomarker [70] and is also considered to be a promising target for cancer 
therapeutics [82]. 
On the other hand, survivin is essential during normal embryogenesis, which 
is clearly demonstrated by lethality of the homozygous knockout mice. [83]. 
Later on, several studies have shown the requirement of survivin for normal 
proliferation of several different cell types also in adults. Conditional 
knockouts show that survivin is essential for adult haematopoiesis [84]. We 
(paper I), and others [85] have shown that survivin is expressed in terminally 
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differentiated DCs, and is linked to their maintenance (paper I). Further, 
survivin is expressed in terminally differentiated neutrophils [86] and crucial 
for T cell development [87,88]. Survivin transcription seems to be active in 
constantly renewing tissues like the testis, spleen, bone marrow and thymus, 
but almost absent in fully differentiated tissue that rarely divide such as brain, 
heart, kidney, ovary and skeletal muscle [89,90]  
In conclusion, although overexpressed in most cancers, survivin also is 
important for normal adult tissue homeostasis of constantly renewing tissues. 
3.1.2 Survivin in cell division and apoptosis 
The knockout of the other anti-apoptotic IAPs is not lethal, but the survivin 
knockout is [91]. The severe defects at the embryonic stage with reduced 
number of nuclei and polyploidy in animals lacking survivin, demonstrate 
that the protein is necessary during cell division [83] shRNA knockdown 
studies in a primary cell line and in in normal differentiated cells showed that 
survivin is essential for proliferation and proper chromosome segregation and 
cells lacking survivin will suffer severe defects [92]. In the HeLa human 
cervical cancer cell line - survivin is expressed in a cell-cycle dependent 
manner with a peak at G2/M [93]. Survivin is a part of the chromosomal 
Figure 5. Survivin in cell division and apoptosis. Survivin in complex with 
Borealin, inner centromere protein (INCENP) and Aurora B kinase forms the 
chromosomal passenger complex that binds to the centromere and segregates the 
chromosomes between daughter cells at mitosis. Survivin also takes part as an 
inhibitor in apoptosis in complex with caspase inhibitors HBXIP and XIAP. 
Caspases are activated by death receptors through caspase-8 (extrinsic 
pathways), or cellular stress leading to release of Cytochrome c and the IAP 
inhibitor SMAC from the mitochondria (intrinsic pathways). 
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passenger complex, which during cells division facilitates the segregation of 
chromosomes [94] (Figure 5). The chromosome segregating function of 
survivin is evolutionary conserved and the essentiality of survivin homologs 
during mitosis has been shown in yeast [95] and Caenorhabditis elegans [96]  
Also, cell-cycle independent expression of survivin has been described. It can 
be observed after stimulation with cytokines or growth factors [97,98] and 
studies in transgenic mice suggest that survivin also may be up-regulated 
during interphase in vivo [99] and that the expression overlaps with stem cell 
markers [100]. At the N-terminus survivin has a BIR domain, which is a 73 
amino acid (15-87) domain containing a zinc-binding motif, and that 
characterises the members of the inhibitors of apoptosis proteins. In contrast 
to other IAPs with known anti-apoptotic function survivin has only one BIR 
domain, [101] and lacks also other domains present in IAPs, like a C-
terminus RING domain and a CARD domain. Transgenic expression of 
survivin has been shown to counteract apoptosis in several experimental 
settings like in ultra violet B (UVB) light induced apoptosis in kerationcytes 
[102]. Attempts to show that survivin can inhibit apoptosis on its own have 
not been fruitful, instead it has been suggested that it does promote survival 
through modulation of other proteins. [103]. Survivin is released from 
mitochondria in response to death stimuli through intrinsic or extrinsic 
pathways and inhibit apoptosis in complex with hepatitis B X interacting 
protein [104] or in complex with another inhibitor of apoptosis; XIAP [105] 
perhaps by separating Smac/Diablo from XIAP, thus enabling caspase 
degradation [106]. (figure 5). 
3.2 What regulates the intracellular functions of survivin? 
It is not clear how survivin exerts its different actions, but there are many 
hypothesis. Cellular localisation might be one determinant [107]. It has been 
shown that cytoplasmic survivin inhibits cell death [108], promote tumour 
progression [109] and accumulates in cell culture [110], mitochondrial 
survivin play a role in apoptosis [71], whereas nuclear survivin in some 
studies is associated with the chromosomal passenger complex that regulates 
cell division [111]. It has been proposed that function is depending on 
whether survivin acts as a monomer or a dimer [112]. Also, posttranslational 
modifications, such as phosphorylation, seem to be important for its functions 
in cell cycle and apoptosis [113] 
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The survivin gene generates several alternatively spliced transcripts that are 
translated into several isoforms and these isoforms might be the key 
determinant of the many functions of survivin [114]. It has been suggested 
that the splice variants can have different properties and that that splice 
variants can interact with and modulate the functions of full-length of 
survivin [115,116]. In the human there are at least five different transcripts; 
survivin, survivin-2B, Survivin-∆Ex3, Survivin-3B, survivin-2α and (Figure 
6A). There are somewhat conflicting reports about their exact biological 
function. The splice variants all share homology in the N-terminus, but they 
differ at the C-terminus. Almost all of them, are associated with unfavourable 
disease outcome of cancer [114], but the Survivin 2B variant might be a 
natural antagonist of the anti-apoptotic survivin and has been seen to promote 
apoptosis experimentally [117] and is in some cases associated with a better 
disease outcome in some cancer types [114]. In mice there are three known 
transcripts of the survivin gene: survivin140, survivin121 and survivin40 [89] 
(Figure 6B). The survivin 40 variant is expressed in mouse embryos [89] and 
bone marrow (paper I). But, we (paper I), and others [89] could not detect 
any protein of that size (paper I) 
  
Figure 6. Splice 
variants of (A) 
human and (B) 
mouse survivin. 
Sites of the primer 
binding sequences 
for gene expression 
analysis of the 
mouse survivin 
splice variants are 
marked (paper I).  
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3.3 Survivin in RA 
In 2005 Bokarewa et al [73] discovered that extracellular survivin was 
present in the blood and synovial fluid, in around 21% of RA patients 
(n=131), with levels exceeding those in healthy controls. Furthermore, 
survivin levels was associated with the degree of bone and cartilage erosivity 
[73]. Analysis of survivin in serum in 651 patients from the BARFOT cohort 
of showed that 60% of the patients with early RA were positive for survivin. 
The cohort was followed for 5 years and the survivin positive group 
developed erosions faster than the survivin negative group [118]. New 
studies have shown that extracellular serum survivin could even precede the 
onset of RA and predict development of disease [119]. 
Several studies have confirmed the presence of extracellular survivin in RA 
patients and the link to erosivity (paper I, paper III) [73,74,118], disease 
activity [74,120], presence of aCCP [118,120], RF (paper I)[118] and 
smoking [121]. No significant correlations to neither age [118,122] nor to 
inflammation – measured as CRP – were found (paper I) [73,74] The levels 
of circulating survivin in RA patients are similar to the levels in the joints 
(paper III) [73] but there is a strong correlation between the blood survivin 
and synovial fluid [73,122] survivin suggesting the joint to be the source of 
survivin secretion.  
The survivin levels in synovial fluid in RA patient were significantly higher 
compared those obtained osteoarthritic patients [74]. Survivin is expressed in 
the lining layer of synovial tissue from RA patients (paper III) [2,74] and has 
also been confirmed by gene expression analysis of RA synovial tissue [2] In 
murine histology sections from mice with collagen-induced arthritis, survivin 
is expressed in the tissue surrounding ectopic lymphoid structures. In mBSA 
induced arthritis survivin is found in the synovial lining layer, in the 
chondrocytes and in bone marrow (Figure 7).  
Figure 7. Survivin 
expression in the joints of 
murine collagen induced 
arthritis and mBSA 
induced arthritis  
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3.3.1 Autoantibodies against survivin 
Autoantibodies against survivin of both IgG and IgM isotypes are found in 
RA patients, and are increased in patients without erosions. There are no 
correlations between the serum levels of survivin and the anti-survivin 
autoantibodies [73]. Anti-survivin autoantibodies are found in a substantial 
portion (41%) of patients with systemic sclerosis, rarely in patients with SLE 
[123,124] and were not detected in patients with Sjögren’s syndrome [124]. 
In a study of women with endometriosis and healthy controls anti-survivin 
autoantibodies were negatively associated with smoking [125], thus smoking 
might be a confounding factor for survivin autoantibody levels. 
3.4 Survivin in other autoimmune diseases 
Survivin is detected in blood plasma and synovial fluid of and patients with 
juvenile arthritis and the levels of survivin was associated to a more severe 
course of disease [126]. Survivin is expressed in psoriatic skin and decrease 
upon infliximab treatment [127]. It is also expressed in oral lichen planus 
lesions [128] and is increased in T lymphocytes from patients with multiple 
sclerosis [129]. 
3.5 A link between Flt3 ligand and survivin in RA? 
Flt3L is a hematopoietic differentiation factor stimulating growth of 
hematopoietic progenitor and DCs [130,131]. Analysis of Flt3L in paired 
serum and synovial fluid samples in a cohort of RA patients with established 
disease showed that Flt3L is strongly expressed at the site of inflammation 
[132]. In addition, in an experimental setting Flt3L exerts both pro-
inflammatory and tissue destructive properties once in the joint cavity [132]. 
Also, Flt3 has been shown to be a marker with predictive value for 
development of RA [133].  
Mutations in Flt3 are found in 30% of patients with acute myeloid leukaemia 
[134] and cells expressing Flt3 with internal tandem duplication mutations, 
which keep Flt3 signalling constantly active, have an increased survivin 
expression [135]. We found that in the survivin positive RA patients, the 
levels of Flt3L in are also elevated. Thus, there is a positive association 
between the levels of survivin and Flt3L in blood (p=0.003) (Paper I).  
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3.6 A link between urokinase plasminogen activator and 
survivin in erosive RA? 
uPA is a serine proteinase responsible for activation of plasminogen. This 
leads directly to lysis of fibrin clots, but also to the breakdown of the 
extracellular matrix and invasive migration of cells. This plays an important 
role in wound healing and inflammation, but also in cancer development and 
metastasis.[136]. The link between survivin and uPA was noted in breast 
cancer [137], but there are reasons to suspect that those two could also be 
linked in RA. The synovial tissue in RA patients has an increased uPA 
activity in the proliferating lining layer [138] (paper III). uPA has been 
shown to induce arthritis after intraarticular injection in healthy mice [139]. 
Since erosivity in RA seems to be linked to high serum levels of survivin we 
postulated that survivin could be involved in cell transformation leading to 
increased migration of synovial cells and breakdown of the extracellular 
matrix- that is in processes typically linked to the activity of uPA. Indeed, 
survivin and urokinase are both elevated in the patients with erosive RA and 
there is a correlation  (r = 0.46, P = 0.0015) between the two proteins (Paper 
III).  
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4 FLT3L AND DENDRITIC CELLS 
4.1  The expression of Flt3L in RA 
Although, the exact cellular source of Flt3L in RA patients has not yet been 
determined, Dehlin et al. observed that the levels of soluble Flt3L are 
significantly higher in synovial fluid from patients with RA compared to 
synovial fluid from patients with joint damage caused by osteoarthritis or 
traumatic joint injury, while the serum levels of Flt3L did not differ between 
the patients and the controls [132]. These findings suggest the synovial cells 
could be a major source of Flt3L in RA. Flt3L is expressed both as an 
intracellulary stored soluble protein (sFlt3L) and as a membrane bound 
protein (mFlt3L) and the balance between them are mediated through 
alternative splicing [140,141]. The Flt3L is released in vivo in response to 
intracellular infections such as malaria [142] or viral infections, in response 
to stimulation with TLR ligands [143] and after bone marrow ablation [144]. 
Human synovial fibroblasts express mFlt3L on their surface in culture 
(previously unpublished, Figure 8), but release barely detectable amounts 
spontaneously. Also bone marrow stromal cells [145,146] and thymic stromal 
cells [147] express mFlt3L and sFlt3L. Both human [148] and mouse 
(unpublished data) T lymphocytes express mFlt3L and have intracellularly 
stored sFlt3L. It is not known whether soluble Flt3L in RA patients is 
generated through alternative splicing or through shedding of the membrane 
bound form. In T cells sFlt3L can be released when the cells are stimulated 
with cytokines that signal through the common cytokine receptor γ-chain (IL-
2, IL-7, IL-4 and IL-15) [148] and uric acid was recently shown to mediate 
Flt3L release from mast cells [142]. Soluble Flt3L can also be generated 
through shedding of the membrane bound protein by proteases like TNFα 
converting enzyme (TACE/ ADAM17) [149].  
Figure 8. Surface staining of Flt3L (tinted) and control IgG (dashed) on in 
vitro cultured synovial fibroblasts and the primary human cell line MRC-5. 
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4.2 What cells does Flt3L affect? 
The only known receptor for Flt3L is Fms-like tyrosine kinase 3 (Flt3, also 
known as FLK-2, STK1 or CD135), that is a receptor tyrosine kinase class 
III. These include c-KIT, FLT3, PDGFRα/β and c-fms receptors. Binding of 
Flt3L causes auto-phosphorylation of the tyrosine residues of the intracellular 
domain of Flt3 and both mFlt3L and sFlt3L exhibit this activity [150]. Flt3 
was originally cloned by two independent groups, found to be expressed by 
hematopoietic progenitors [151] and named by the similarity to c-fms [152]. 
Multipotent progenitors that are generated through haematopoietic stem cell 
division express Flt3 among other growth factor receptors and the signal that 
they receive from their ligands determine the fate of cell [153]. Flt3 is the key 
receptor for the differentiation of the professional antigen presenting DCs 
from bone marrow progenitors [153] (Figure 9). Mice lacking Flt3 show a 
marked reduction in the number of DC in peripheral lymphoid organs [154] 
and ectopic expression of Flt3 restore DC potential in haematopoetic 
progenitors [155] The expression of Flt3 also remain on fully differentiated 
Figure 9. Flt3, together with other growth factor receptors, are expressed 
on haematopoietic precursors in the bone marrow guiding their 
development into different cell types. Flt3 is essential for the 
differentiation of DCs and is also expressed on peripheral cDCs and 
pDCs. MPP = multipotent precursors, CMP=common myeloid 
progenitors, CLP= common lymphoid progenitors, MDP= macrophage-
dendritic cell precursors, CDP=common dendritic cells precursor. 
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DCs [153,156] and is present on the surface of the CD11chi DCs in lymphoid 
organs [62]. In addition, a small fraction of splenic B cells express Flt3 and 
they up-regulate surface expression after in vitro stimulation with LPS or 
CD40 and IL-4 [157]. Mice lacking Flt3 have a reduction in B cell 
progenitors but normal numbers of mature B cells [158]. Flt3L treatment 
promote the differentiation of DCs in vivo in mice [130] and humans [131]. 
Mice that lack Flt3L have reduced cellularity in the bone marrow, peripheral 
blood, lymph nodes and spleen, and a particularly large reduction in the 
number of DCs, but also in NK cells [159]. The slight differences in the 
phenotypes of the Flt3 and Flt3L knockouts suggest that Flt3L can affect 
other receptors. DCs can be generated in vitro by 8-10 days culture in Flt3L 
supplemented medium. This will generate DCs that represent steady state 
splenic DCs with respect to TLR expression, transcription factors and 
function [160].  
4.3 DC development and subtypes 
The DC is the most important antigen-presenting cell in the immune system 
and a bridge between the innate immune sensing and the adaptive immune 
system triggering either immunity or tolerance. Most information regarding 
different DC subtypes come from mouse experiments and when it comes to 
human DC subsets the blood derived DCs are the most studied. Mouse 
lymphoid-tissue DCs can broadly be divided into plasmacytoid DCs (pDCs) 
and conventional DCs (cDCs). pDCs express low to intermediate CD11c, 
MHC II, B220 and PDCA1 (Figure 10A). The cDCs has a high expression 
CD11c and are MHC II positive (Figure 10A) and can be further divided in to 
CD8α+CD4–CD11b– (CD8+ DC), CD8α–CD4+CD11b+ and CD8α–CD4–
CD11b+ cDCs [161]. The two latter CD8- cDC populations are sometimes 
grouped and called the CD11b+ cDCs, or alternatively the CD4+ cDCs and 
the CD8-CD4- cDCs (Figure 10B) [162]. The CD8+ cDC are the most well 
Figure 10. Flow 
cytometry gating of DC 
subsets in mouse 
spleen. A) pDCs are 
MHCII and CD11cint, 
cDCs are MHCII+ and 
CD11chi B) cDCs can 
be further subdivided 
into CD8+, CD4+ and 
CD8-CD4- 
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studied subset, which have the same origin and a similar phenotype as the 
CD103+CD11b- in tissues. They are dependent on the transcription factor 
IRF8 and are highly sensitive to Flt3L stimulation [62] and are almost absent 
in Flt3L knockout mice [159]. The CD4+CD8- and CD8-CD4- cDCs are a 
more heterogeneous population that also dependent on Flt3L possibly in 
combination with GM-CSF [153]. These DC they express the IRF4 
transcription factor and they correspond to the CD103+CD11b+ DCs found 
in tissues [163]. 
Differentiation of the skin epidermal Langerhans cell is independent of 
Flt3L-Flt3 signalling, since they are unaffected in Flt3 knockout mice [163]. 
Langerhans cells are also present in the human syndrome of DC, monocyte, 
B and NK lymphoid deficiency (DCML), a condition, which in many ways 
resemble Flt3L/Flt3 knockout phenotypes [164]. Monocytes that enter lymph 
nodes can differentiate into a DC phenotype under inflammatory conditions 
(mo-DCs) [165] DCs that are generated from bone marrow in vitro cultures 
supplemented with GM-CSF with or without IL-4, resemble the monocyte 
derived DCs [166] and the DCs derived from GM-CSF supplemented PBMC 
cultures are distinct from the Flt3L derived DCs and they loose the 
expression of Flt3 [167]. Also in vivo, Flt3L and GM-CSF results in different 
DC populations, with different cytokines profiles [168], they promote 
different antibody subclasses [169], and Flt3L-induced DCs migrated more 
efficiently to lymph nodes [168] . Since the GM-CSF knockout mice only has 
a minor reduction in splenic DC frequencies in the spleen the Flt3L is 
probably the most important cytokine for maintaining DC number in 
lymphoid organs [170]  
4.4 Flt3L as a chemoattractant 
Flt3L is highly released/expressed at the site of inflammation [132] and Flt3+ 
cells are present in synovial tissue from RA patients [167]. Injection with 
Flt3L directly into the knee joint enhance inflammatory cell infiltrate in mice 
[132] and injection of Flt3L into human subjects enlarges lymph nodes and 
gives a reaction at the injection site [131]. We observed an enhanced 
migration of freshly isolated mouse bone marrow cells towards a higher 
Flt3L gradient in a transwell system (paper II). This means that Flt3L could 
possibly function as a chemoattractant for Flt3 positive cells from the blood 
or from the bone marrow into the joint space. Other researchers have also 
observed enhanced migration towards Flt3L of human CD34+ cells [171], 
but also without gradient, so it cannot be excluded that Flt3L besides 
chemotactic properties also can display chemokinetic properties.    
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4.5 DC activation and response  
In response to growth factors DCs leave the bone marrow and travel via the 
blood to nearby tissues and lymphoid organs [172], where they attain their 
typical morphology and reside and wait for a pathogen encounter. Before any 
pathogen encounter the DCs are immature, meaning that they express MHCI 
and MHCII, without providing co-stimulatory molecules. Stimulation of DC 
through PRR, either attached to the cell surface or present inside the cell, 
leads to DC maturation. In addition to presentation of the retrieved antigen on 
MHC II, the mature DCs express co-stimulatory molecules such as B7-1 
(CD80) and B7-2 (CD86) and CD40. DCs also express chemokine receptors 
and e.g. CCR7 makes them home to a nearby lymph node. In the lymph node 
the activated DC can encounter naive T cells with a cognate TCR that can 
receive the activating signals through CD28 that interacts with B7 molecules 
on the DC. Activated T cells can stimulate DCs to produce cytokines through 
the CD40L interacting with CD40 on the DC. The different DC subsets are 
described in more detail in the mouse [163,173] and below follows some 
characteristics of the major DC subsets in mice: 
• pDCs produce type I interferons in response to viral and bacterial 
infections, caused by activation of the nucleic acid-sensing TLRs; 
TLR7 and TLR9 [174].  
• CD8+ cDCs are good at cross-presenting antigens from intracellular 
microbes to CD8+ T cells through a phagosome-to-cytosole pathway 
[175], they express TLR3, TLR9, TLR11 and TLR13 and produce 
IL-12 and are therefore important for the TH1 response.  
• The CD4+ and CD8-DC4- cDCs present peptides on MHC II to 
CD4+ T cells, express various TLRs, and inflammasome activating 
PRRs, and a tissue equivalent IRF4 dependent DC express IL-6 and 
is important for the activation of the TH17 response [176]. 
 
When antigens are presented to a naïve helper T cells in the peripheral lymph 
node the T lymphocytes differentiate into different subclasses of T helper 
lymphocytes depending on the cytokines released by the DC, the co-
stimulatory molecules they express and the strength binding in the MHC-
TCR complex. The naïve CD4+ T lymphocytes differentiate into different 
subclasses. The different T helper subsets have different cytokine profiles and 
transcription factors governing lineage commitment of these subsets have 
been identified (Figure 11). The lineage commitment of effector T 
lymphocytes is important for initiation of an appropriate programme of 
defence against the intruder.  
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4.6 Tolerance induction by DC 
Besides their function as initiators of adaptive immune responses, DCs are 
important for the maintenance of central and peripheral tolerance and e.g. 
absence of CD11c+ cells in mice causes autoimmunity [177]. Flt3L treatment 
in vivo increases the numbers of regulatory T lymphocytes (Tregs) in mice 
[62,178] and in humans [179]. This is believed to be mediated by the 
expanded DC population and in particular the pDCs [178,179] as Tregs can 
proliferate in vitro by addition of antigen loaded DCs [180].  
Tregs are T helper cells that are commonly characterized by high expression 
CD25 and the intracellular transcription factor Foxp3. [181] Tregs suppress 
immunity through several different mechanisms. They secrete suppressive 
cytokines like TGFβ and IL-10 and they consume IL-2 [182]. They also 
constitutively express the receptor CTLA-4 of the CD28 family. CTLA-4 is a 
receptor with high affinity for the B7 molecules and binding will prevent co-
stimulation of naïve T cells via CD28, and thus inhibit their activation.[183] 
The Treg has also been shown to reduce the APC function by removing B7 
from its surface [184] 
Although the exact mechanism is not known, DCs are most likely involved 
both in Treg differentiation [185] and clonal deletion in the thymus [186]. 
DCs are important also for the induction of Tregs in the periphery [187] 
together with the presence of TGFβ [188]. Interaction of PD-1 with the PD-
L1 on the DC is essential for the induction and sustained function of 
peripheral Tregs [189]. The immature DC that has not been activated by any 
Figure 11. Differentiation 
of naïve CD4+ T cells 
into helper T subsets. 
Lineage commitment 
depends on the cytokine 
signals given by the DCs. 
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pathogen-associated signals are important to maintain tolerance since their 
low levels of co-stimulatory molecules induce anergy in T cells [190]. 
4.7 Inhibition of Flt3 signalling reduces the frequency of  
DCs and the degree of synovitis in mBSA arthritis 
Flt3 expression can be upregulated by inflammatory mediators like PGE2 
[85] which is released by synoviocytes in response to proinflammatory 
cytokines in RA [191] and is produced during mBSA arthritis [67]. It is 
known that Flt3 is essential for the development of DCs [154]. Sunitinib, a 
synthetic inhibitor of Flt3, reduces the frequency of DCs (Figure 12) in 
Figure 12. Representational illustration of Flow cytometry gating strategy for 
the analysis of pDC and cDC frequencies in the spleen after sunitinib 
treatment.A) Cells were fist gated on singlets, then gated by FSC and SSC to 
remove dead cells and debris. B) A gate was made for the B220+CD11c+ 
(pDCs) and the B220-CD11c+ (cDC). C) cDCs where further gated after the 
expression of CD8α and CD4 into CD8α+CD4–CD11b– (CD8+ DC), CD8α–
CD4+CD11b+ and CD8α–CD4–CD11b+ cDCs . The frequencies in the gate 
are relative to the SSC/FSC gate in A. Statistics are shown in paper II 
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mouse spleen while there are no major differences in the frequency of B 
cells, T cells or granulocytes (Paper I). Flt3 inhibition by sunitinib results in 
major decrease in all of the DC subsets (Figure 12 and paper II) that could be 
explained by the dependency of all subpopulations on Flt3L stimuli [153] and 
the rapid turnover of DCs [192].  
Sunitinib treatment initiated at day 7, the 2nd immunisation, reduces the 
synovial inflammation in a dose dependent manner and the levels of antigen 
specific antibodies. However, starting sunitinib treatment at the time of 
arthritis induction does not reduce synovitis, but instead tended to increase 
the inflammatory cell infiltration (paper II).  
One of the primary features of the human DC deficiency syndromes, like 
DCML syndrome and the IRF8 mutation, is susceptibility to mycobacterial 
infections, probably caused by a lack of DCs and subsequent defects of the 
IL-12/Th1/IFNγ axis [193]. The DCML syndrome is most likely caused by a 
defect in a progenitor common to DC, monocytes, B cell and NK cell 
lineages and can be treated by hematopoietic stem cell transplantation [164]. 
Flt3L knockout mice have similar cellular defects as DCML patients and they 
both have reduced number of regulatory T cells [164,194]. Mice with a loss 
of function mutation in Flt3 show a susceptibility to mouse cytomegalovirus 
infections [143] and Flt3L treatment increased survival after challenge with 
Listera monocytogenes and herpes simplex virus type 1 in newborn mice 
[195]. Ectopic expression of Flt3L generated a stronger Th1 respons to 
Mycobacterium tuberculosis antigen in adult mice [196]  
It is possible that the DC deficiency induced by sunitinib in the mBSA model 
reduces the response to Freunds adjuvant, which is important for proper 
immunisation, which is crucial for arthritis development after mBSA 
injection. When sunitinib was given at day 7, from the 2nd immunisation, the 
inflammatory reaction following intraarticular injection of mBSA was 
impaired and serum levels of anti-mBSA antibodies were lower, which is a 
clear sign that sunitinib reduced the response to mBSA.  In contrast, when 
sunitinib treatment was initiated at the time of arthritis induction, when the 
adaptive immune response was already established, there was no effect on 
synovitis (paper II).   
Taken together, this suggests that the inhibition of Flt3 signalling limit 
development of arthritis when administered during the immunisation phase 
by interfering with DC development. However, the effects of Flt3 inhibition 
by sunitinib on already an established immune response are limited.  
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4.8 Sunitinib could potentially reduce bone destruction 
The frequency of bone destructions in sunitinib treated mice seems to be 
uncoupled from the degree of synovitis (paper II). Sunitinib is known inhibit 
all RTKs type III to a different extent, which include the receptors for M-CSF 
and VEGF [197]. M-CSF and RANKL are potent inducers of 
osteoclastogenesis in mouse bone marrow cultured in vitro, which result in 
the generation of bone resorptive osteoclasts [198]. The serum levels of 
RANKL in mice receiving the higher sunitinib dose do not differ from serum 
levels in control mice, so that does not explain any influence on bone 
destructions. Sunitinib mediated inhibition of M-CSF could potentially have 
an effect on the osteoclastogenesis during arthritis. Indeed, it has been shown 
that sunitinib can reduce the number of osteoclasts mice [199,200].  VEGF, 
also inhibited by sunitinib, has been shown to enhance the bone resorption by 
mature osteoclasts [201]. Taken together, it is possible that other actions of 
sunitinib besides Flt3 inhibition that could have impact on bone destruction. 
4.9 Sunitinib the increase the serum levels of Flt3L 
The serum levels of Flt3L increased after treating mice with the Flt3 inhibitor 
sunitinib, (Figure 13 and paper II), which can be interpreted as a negative 
feedback loop where tissues in lack of DCs release more Flt3L or 
alternatively a lack of Flt3 positive DCs that consume Flt3L [202]. It is e.g. 
known that both after DC ablation in mice [177,203] and in human DC 
deficiencies [164,204] the serum levels of Flt3L are also elevated. The exact 
mechanism of this feedback loop is not known. But there seem to be no direct 
effect since there are no differences in release of Flt3L from synovial 
fibroblasts after adding sunitinib in vitro (unpublished data).  
Figure 13. Serum levels of Flt3L in 
mBSA arthritis mice treated with 
Flt3 inhibitor sunitinib (sun) at 10 
mg/kg/day or 40 mg/kg/day starting 
from the second immunisation at 
day 7 or at the arthritis induction at 
day 21. A kruskal-Wallis test was 
used to calculate P-values 
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4.10 Survivin is up-regulated in bone marrow and splenic 
DC following Flt3 activation 
STAT3 is phosphorylated by Flt3 signalling [155] and is essential for 
development of both pDCs and cDCs in lymphoid tissues. Mice lacking 
STAT3 cannot produce sufficient amounts of DCs, even after Flt3L 
injections [205] while expression of STAT3 induced by viral transduction 
could provoke DC development in Flt3 negative bone marrow progenitors 
[155].  Phosphorylated STAT3 can bind to the STAT response element in the 
survivin promoter and induce expression of survivin in haematopoietic 
progenitor cells [206] Daily systemic Flt3L injections upregulates survivin 
expression in mouse bone marrow (Figure 14). The MHC II+CD11chi cDCs 
in the spleen express high levels of survivin compared to total splenocytes in 
the mononuclear gate, at baseline (paper I). And the levels of intracellular 
survivin in the cDCs are significantly upregulated by daily systemic flt3L 
injection to Balb/c mBSA mice. (Figure 15 and paper II). 
Mice treated with sunitinib have a lower expression of survivin in the bone 
marrow and in the cDCs (paper II), which shows that the upregulation of 
survivin is mediated through the receptor. The frequency of DCs in the spleen 
are reduced by sunitinib treatment (Paper II) and increased in the spleen and 
lymph nodes by daily injections with recombinant Flt3L [62]. Thus survivin 
expression by Flt3 signalling is strongly linked to the number of DCs in 
lymphoid organs (paper I, II)[62], but is that due to proliferation or 
differentiation of DCs?  
DC depletion experiments have shown that, except for the Langerhans cells, 
DC homeostasis and DC numbers are maintained by continuous 
differentiation of DC from bone marrow precursors rather than proliferation 
of differentiated DCs [202]. The mature DCs also have the ability to divide in 
lymphoid organs (spleen and lymph nodes) which was shown by injecting 
mice with BrdU [172]. However, several studies imply that survivin 
expression in Flt3+ progenitors mainly promote survival during 
differentiation. For instance, in Flt3L knockout animals BrdU incorporation 
in Flt3+ bone marrow progentitors was similar to the incorporation in the 
wildtype animals, but apoptosis markers were elevated [207]. Singh et al 
showed that Flt3L induced DC development in vitro from haematopoietic 
progenitors could be enhanced by addition of prostaglandin E2 that enhanced 
survivin expression, and was associated with reduced apoptosis but not with 
proliferation [85].  
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Figure 15. Flow cytometry analysis of intracellular survivin in the 
MHCII+CD11chi population in spleen from mice treated with PBS or Flt3L. 
Figure 14. Flow cytometry analysis of bone marrow from mBSA arthritic Balb/c 
mice that daily were injected with PBS or Flt3L. A) SSC/FSC gate of bone 
marrow mononuclear cells. B) Bone marrow with positive and negative gate for 
surface Flt3. C) Intracellular survivin in bone marrow mononuclear cells 
Sofia Andersson 
31 
Survivin in DCs might also be linked to maturation and enhanced antigen-
presenting capacity. Splenocytes stimulated with TLR ligands up-regulated 
intracellular survivin after stimulation with agonists for TLR9, TLR4 and 
TLR2 (Sofia Andersson, unpublished data). In human DCs differentiated in 
vitro with GM-CSF/IL-4 an increase of survivin was observed after 
stimulation with TNFα [208]. The survivin expression in DC is associated 
with an increased frequency of splenic DCs (paper I, paper II) [62] and 
increased surface expression of the integrin CD11c, as well as increased 
expression of MHC II [62]. In RA, local Flt3L might lead to survival of 
autoantigen presenting cells and the modulation of DC turnover. In addition, 
inflammatory mediators like PGE2 enhance the expression of Flt3 and render 
the DCs more susceptible to Flt3L induced resistance to apoptosis. 
4.11 Survivin mediates the effect by tyrosine kinase 
activation  
The specific up-regulation of survivin by Flt3L in cell populations sensitive 
to Flt3L shows that tyrosine kinase signalling is a powerful inducer of 
survivin production. Survivin has also been observed to mediate the effects of 
other RTKs besides Flt3. RNAi targeting survivin remove the cytoprotetive 
effect of VEGF on human endothelial cells [209] GM-CSF signalling induces 
survivin expression via STAT3 and STAT3 siRNA induces and apoptosis 
Figure 16. Flt3 signalling 
and inhibition by 
sunitinib. Binding of Flt3 
induced dimerization of 
the receptor and 
autophosphorylation of 
the intracellular tyrosine 
residues. A 
phosphorylation cascade 
will lead to 
phosphorylation of 
STAT3 and survivin 
expression. Sunitinib 
prevents 
autophosphrylation. 
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Figure 14. Flow cytometry analysis of bone marrow from mBSA arthritic Balb/c 
mice that daily were injected with PBS or Flt3L. A) SSC/FSC gate of bone 
marrow mononuclear cells. B) Bone marrow with positive and negative gate for 
surface Flt3. C) Intracellular survivin in bone marrow mononuclear cells 
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Survivin in DCs might also be linked to maturation and enhanced antigen-
presenting capacity. Splenocytes stimulated with TLR ligands up-regulated 
intracellular survivin after stimulation with agonists for TLR9, TLR4 and 
TLR2 (Sofia Andersson, unpublished data). In human DCs differentiated in 
vitro with GM-CSF/IL-4 an increase of survivin was observed after 
stimulation with TNFα [208]. The survivin expression in DC is associated 
with an increased frequency of splenic DCs (paper I, paper II) [62] and 
increased surface expression of the integrin CD11c, as well as increased 
expression of MHC II [62]. In RA, local Flt3L might lead to survival of 
autoantigen presenting cells and the modulation of DC turnover. In addition, 
inflammatory mediators like PGE2 enhance the expression of Flt3 and render 
the DCs more susceptible to Flt3L induced resistance to apoptosis. 
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Figure 16. Flt3 signalling 
and inhibition by 
sunitinib. Binding of Flt3 
induced dimerization of 
the receptor and 
autophosphorylation of 
the intracellular tyrosine 
residues. A 
phosphorylation cascade 
will lead to 
phosphorylation of 
STAT3 and survivin 
expression. Sunitinib 
prevents 
autophosphrylation. 
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[206] SCF, GM-CSF and G-CSF causes upregulation of survivin in bone 
marrow cells from patients with AML [98]. 
4.12 Immunity or tolerance by Flt3L? 
The effects of Flt3 signalling in mBSA arthritis are contradictory: On the one 
hand, as was discussed above, Flt3 inhibition by sunitinib significantly 
reduces the mBSA arthritis synovitis-score in a dose dependent manner when 
treatment is initiated at immunisation, accompanied by lower levels of mBSA 
antibodies (paper II). On the other hand, mice injected with recombinant 
Flt3L show a tendency to reduced joint damage in the mBSA arthritis model, 
and they also display significantly lower levels of mBSA antibodies [62]. The 
fact that the seemingly opposite treatments, resulting in reversed DC number 
and survivin expression, they nevertheless show similar anti-arthritogenic 
effects, requires an additional explanation. DCs can in contact with naïve T 
cells give rise to many different responses and transcriptional programmes in 
the T cell, depending on the activation state and the subtype of the DC, as 
discussed earlier. Flt3L treatment in mice is accompanied with an increased 
number of regulatory T cells [210], which can explain the attenuated 
response to mBSA immunization [62]. The Tregs effect on mBSA arthritis is 
probably due to the fact that Flt3L treatment is starting before the immune 
response to mBSA is established. However, Tregs injected at the arthritis 
induction was n ot sufficient to cure established mBSA arthritis [211].  
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5 UROKINASE SIGNALLING AND SURVIVIN   
5.1 Survivin and the uPA/uPAR system in fibroblasts 
Urokinase plasminogen activator (uPA) is a serine protease and it cleaves the 
zymogen plasminogen to plasmin. Plasmin in turn, can degrade fibrin clots, 
degrade extracellular matrix components and cleave pro-MMPs into active 
MMPs that can cleave collagen (figure 18). Besides its proteolytic actions, 
uPA can bind to the uPA receptor (uPAR, CD87), a glycoprotein lacking an 
intracellular domain. The binding of uPA to uPAR has two functions for the 
cell: 1) it localizes uPA activity to the cell surface, which can be used by the 
cell as a way to degrade extracellular matrix at the leading edge during 
migration [212]; 2) it can induce intracellular signalling via integrins as co-
receptors, leading to cell adhesion, migration and proliferation (figure 17). 
The system is utilized by cancer cells to enhance invasive properties during 
metastasis, and is also expressed by synoviocytes in RA in vivo [138] and by 
cultured RA-FLS [213,214]. It has been shown that uPA is essential for the 
development of collagen-induced arthritis [215] and that uPA injected into a 
mouse joint can trigger arthritis [139] (paper III).  
Survivin is essential for the uPA secretion from fibroblasts (paper III). When 
injected into a SCID mouse joint, human MRC-5 fibroblasts caused arthritis 
with synovitis and cartilage destruction after 3 days, but fibroblasts subjected 
to the survivin targeting siRNA before injection caused a significantly milder 
arthritis (paper III). It is possible that the observed effect of survivin RNA 
interference on arthritis is due to decreased uPA secretion by the injected 
cells. 
Figure 17. A) uPA cleaves the 
zymogen plasminogen to 
plasmin. Plasmin cleaves pro-
MMPs into active MMPs and 
degrades extracellular matrix 
(ECM) components. B) uPA 
bind the uPAR at the cell 
surface and promote 
intracellular signalling 
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5.2 uPAR signalling and survivin 
The expression of uPAR is complex. It has been shown that Hypoxia-
inducible factor 1 (HIF-1) that can bind to the survivin promoter and enhance 
transcription [216] and it has also been shown to enhance expression of 
uPAR [217]. We could show that uPAR expression is dependent on survivin 
(paper III) and survivin is up-regulated by stimulation of uPAR through PI3 
kinase signalling (paper III). Indeed, these findings are interesting as local 
hypoxia characterizes the hyperplastic synovial tissue and might contribute to 
survival of synoviocytes through survivin and uPAR.  
The uPA expressed by synovial fibroblasts can contribute to the arthriogenic 
behaviour of synoviocytes in at least three different ways 1) uPA promotes 
the breakdown of the extracellular matrix 2) uPA can induce survivin after 
binding to its receptor uPAR (paper III), which is expressed by synoviocytes 
in RA tissue, and thus enhance survival and promote increased uPA synthesis 
3) uPA promotes the release of pro-inflammatory cytokines [139], and the 
chemokine IL8 (paper III), which is a major neutrophil chemoattractant in 
humans. The uPA induced IL8 release is independent of uPAR (paper III), 
which means that there might be another not yet discovered mechanism of 
uPA signalling.  
  
Figure 18. Survivin as a regulator of uPA/uPAR signalling in the inflamed 
joint. A) Survivin expression in RA-FLS is induced by several possible 
mechanisms, such as the presence of RTK ligands, uPAR expression, 
epigenetic changes or modulation of tumor suppressor genes e.g. p53. 
Survivin expression enhances uPA release from RA-FLS. B) uPA/uPAR 
signalling enhances survivin expression in monocytes via PI3 kinase, which 
leads to the up-regulation of uPAR and also to the expression of integrins 
such as CD11c+ and CD11b+. uPA up-regulates IL-8 in monocytes 
independently of uPAR signaling. RTK = receptor tyrosine kinase 
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6 GENERAL DISCUSSION 
6.1 Have we found a possible cellular source for the 
extracellular survivin seen in RA patients? 
We have shown that survivin is induced in DCs following Flt3L 
administration (paper I), in monocytes following uPA stimulation (paper III) 
and expressed by synovial fibroblasts (paper III). Intracellular survivin may 
potentially protect inflammatory fibroblasts and autoimmune cells that 
infiltrate the synovia from apoptosis and impair immune regulation. These 
findings suggest that the intracellular functions of survivin are important in 
RA, but what is the source of the extracellular pool seen in the RA patients? 
6.1.1 Flt3L induced survivin in DCs? 
Previous studies have shown that survivin is not released by human PBMCs 
isolated from RA patients or healthy controls after stimulation by TNFa, the 
TLR4 ligand LPS or mitogens such as ConA and PHA [73] The survivin 
positive RA patients have higher frequency of circulating CD11c+ cells and 
higher intracellular expression of survivin in the CD11c+ subset [218], which 
indicate that survivin in DCs can be associated with the extracellular pool of 
survivin. We found that splenocytes from Flt3L treated mice released low but 
detectable levels of survivin (paper I). However, we did not observe any 
changes in serum levels of survivin in Flt3L treated mice or sunitinib treated 
mice (paper I). In a study of pre-symptomatic individuals sampled before the 
onset of RA, serum survivin levels are increased compared to controls, while 
Flt3L levels are not [119]. Thus, there is some evidence suggesting that Flt3L 
stimulated DCs might be associated with increased levels of extracellular 
survivin, but it needs to be further investigated. 
6.1.2 Synovial fibroblasts? 
As there is a correlation between levels of survivin in the blood and synovial 
fluid [73,122] the joint is a plausible source of survivin secretion. We and 
others have noticed the local expression of survivin in the lining layer of the 
RA synovium (paper III) and that synovial fibroblasts cultured in vitro 
express intracellular survivin (paper III). We also found that survivin 
expression could be enhanced by uPA signalling through uPAR (paper III). 
Furthermore, although we did not observe any detectable release of survivin 
into the supernatant in vitro (Sofia Andersson, unpublished data) extracellular 
survivin in RA patients show a correlation to markers of epithelial 
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mesenchymal transition in synoviocytes, such as S100A4 [219] and uPA 
(paper III). Thus, synovial fibroblasts expressing survivin is a potential 
source of extracellular survivin but the explanatory mechanism leading to its 
release is still lacking. 
6.1.3 Cell death? 
Necrotic cell death or cellular damage results in the release of intracellular 
components. In RA there is increased cell death e.g. of chondrocytes due to 
breakdown of cartilage. It is possible that these cells could release their 
intracellular storage of survivin. Other intracellular proteins that are not 
normally secreted as Hsp70 have also been found in synovial fluid from RA 
patients [220]. An increased general cell-death as a consequence of the anti-
rheumatic treatment is a less likely cause since the levels as patients have 
high levels of extracellular survivin before the initiation of treatment [118]. 
Thus, it is likely that cellular damage caused by disease progression can lead 
to the release of survivin. 
6.1.4 Possible functions of extracellular survivin 
There is a possibility that the release of survivin and its different splice 
variants have extracellular functions. Previous studies of PBL pulsed with 
recombinant survivin showed an increased expression of CD11c and CD11b 
in the monocyte- and granulocyte population [218]. The extracellular 
survivin may exhibit properties of an endogenous adjuvant i.e. a danger-
associated molecular pattern. Several intracellular molecules, such as 
HMGB1 and heat shock protein, can trigger arthritis when they are localised 
extracellularly [221]. A receptor or PRR molecule recognising survivin is 
however not yet identified and survivin could possibly also be taken up 
passively. It has been shown that extracellular survivin can be taken up by 
cancer cells and promote cell growth [72]. There are also examples of 
intracellular proteins acting as co-receptors when present outside the cell 
[222].  
A more detailed dissection is needed to understand the cellular processes that 
lead to the release of the extracellular pool of survivin. Measurement of 
specific survivin isoforms in the serum and synovial fluid from RA patients 
could give more information about the origin and maybe also the function, 
since it is known that the isoforms of survivin are unable to take part in 
mitosis [116] and might instead have extracellular functions. Active secretion 
might be possible under certain circumstances Cervical carcinoma cells 
(HeLa cells) can secrete survivin via exosomes [223] and extracellular 
survivin can be taken up by other cells and enhance their proliferation [72].  
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In conclusion, our studies suggest that there elevated levels of extracellular 
survivin in a subgroup of RA patients. The cellular source of survivin in this 
condition is not known, but our data indicate that bone marrow cells, 
dendritic cells, and fibroblasts are possible candidates. We have shown that 
down-regulation of survivin signalling by various methods of intracellular 
targeting as RNA interference and tyrosine kinase inhibitors can ameliorate 
arthritis. However, we still do not know whether extracellular survivin 
actually provides additional arthritogenic danger signals. This may be further 
evaluated by targeting of intracellular and extracellular survivin in models of 
arthritis. 
6.2 Can Flt3 inhibition by sunitinib be a way to target 
survivin production in RA? 
One clinical question that arises from this thesis is whether the targeting of 
Flt3 with sunitinib is a potential therapy for the treatment of RA patients, 
since it is already approved and widely used for the treatment of renal 
carcinoma [197]. However, there are several reasons for not using it:  
First of all, we did not see a change in mice when treatment started at the 
arthritis induction, when the immune response was already established. 
Secondly, even if inflammatory DCs presenting autoantigens are potential 
enhancers of an already established autoimmunity, reducing DC number is by 
far a too crude method of treatment. DCs are essential also for maintaining 
tolerance; it is known that DC deficiency in humans [164,224] or 
experimental depletion in mice [177] will lead to autoimmunity. Sunitinib 
treatment reduces the number of Tregs cells in mice [194] and in renal cell 
carcinoma patients [225]. In fact, reducing the frequency of Tregs could be 
an additional mechanism by which sunitinib exerts its effect on renal cell 
carcinoma [225], although it is generally believed to be mediated by 
inhibition of VEGFR and PDGFR [226]. In RA, there is risk that by 
disturbing the balance of haematopoiesis, even more inflammatory DC 
subsets, less dependent on Flt3 will expand when blocking the Flt3 signalling 
in the bone marrow progenitors.  
Several severe side effects after sunitinib usage, like (nausea and vomiting, 
anemia, neutropenia, thrombocytopenia etc) that are acceptable for the 
treatment of metastatic renal cell carcinoma [227] would not be acceptable in 
the situation of prolonged treatment of RA.   
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One possibility that remains an option for further studies is instead to focus 
on the Flt3L. Flt3L was in previous studies shown to enhance peptidoglycan 
induced inflammation by local injection. However, Flt3L alone could not 
cause joint inflammation [132], which might suggest that PRR ligands are 
needed to induce inflammation and that Flt3L can prolong inflammation by 
recruiting mediators of adaptive immunity. Perhaps by recruiting (paper II) 
and enhance survival of antigen presenting DCs (paper I).  
In these studies we have focused on sFlt3L and the effect on survivin in DCs. 
We do not know whether the mFlt3L has functions in the communication 
between DCs and for example the synovial fibroblasts and T cells in RA, and 
if these cells locally can support the survival of Flt3 positive cells. Ectopic 
expression of mFlt3L as a vaccine adjuvant has been evaluated in mice with 
good results.  As we observed that Flt3L is expressed on the surface of 
synovial fibroblasts, there could be a possible interplay between synovial 
fibroblasts and DCs in RA, where mFLt3L on the synovial fibroblasts 
enhance survivin expression in the DCs. FLS also express CCL19 and 
CCL21, ligands for the lymph node homing molecule CCR7, which is 
expressed on DCs and naïve T cells, making local antigen presentation and 
lineage commitment possible. Maybe local injections of targeting antibodies 
or a decoy receptor, interfering with the interaction between receptor and 
ligand, could function to reduce local expansion of DCs presenting self-
peptides. It is not known whether the Flt3 can transmit signals to cells 
expressing membrane bound Flt3L, but its an intriguing idea that the mode of 
inhibition could play a role. 
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7 CONCLUSIONS 
• Survivin is expressed in bone marrow and DCs in response to 
activation of the receptor tyrosine kinase Flt3 in vivo. 
• Increased survivin levels in DCs coincide with accumulation of DCs 
in mBSA arthritis, but expression of survivin in DC do not determine 
whether the T cell response to mBSA is tolerogenic or immunogenic. 
• Flt3 inhibition with sunitinib decreases the frequency of DCs and the 
priming against mBSA when administered at immunisation. 
• Intracellular survivin boost the arthritogenic properties of fibroblasts. 
Figure 19. This figure summaries the main findings in the thesis. Flt3L is 
expressed within the arthritic joint. Flt3 signalling in hematopoietic progenitors 
will lead to the up-regulation of survivin and differentiation into DCs. DCs will 
accumulate in secondary lymphoid organs, due to differentiation or clonal 
expansion. Flt3L also enhances DC migration into the joint, where survivin 
expression is further enhanced by contact with the RA-FLS expressing 
membrane bound Flt3L. This will potentially enhance local presentation of 
autoantigens to T cells. Activated RA-FLS express survivin and release uPA. 
uPAR is expressed by both RA-FLS and and monocytes in the RA joint. 
Expression of uPAR that can bind uPA will lead to further up-regulation of 
survivin. Monocytes activated by uPA express IL-8 that will lead to neutrophil 
recruitment.  
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and enhance survival of antigen presenting DCs (paper I).  
In these studies we have focused on sFlt3L and the effect on survivin in DCs. 
We do not know whether the mFlt3L has functions in the communication 
between DCs and for example the synovial fibroblasts and T cells in RA, and 
if these cells locally can support the survival of Flt3 positive cells. Ectopic 
expression of mFlt3L as a vaccine adjuvant has been evaluated in mice with 
good results.  As we observed that Flt3L is expressed on the surface of 
synovial fibroblasts, there could be a possible interplay between synovial 
fibroblasts and DCs in RA, where mFLt3L on the synovial fibroblasts 
enhance survivin expression in the DCs. FLS also express CCL19 and 
CCL21, ligands for the lymph node homing molecule CCR7, which is 
expressed on DCs and naïve T cells, making local antigen presentation and 
lineage commitment possible. Maybe local injections of targeting antibodies 
or a decoy receptor, interfering with the interaction between receptor and 
ligand, could function to reduce local expansion of DCs presenting self-
peptides. It is not known whether the Flt3 can transmit signals to cells 
expressing membrane bound Flt3L, but its an intriguing idea that the mode of 
inhibition could play a role. 
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7 CONCLUSIONS 
• Survivin is expressed in bone marrow and DCs in response to 
activation of the receptor tyrosine kinase Flt3 in vivo. 
• Increased survivin levels in DCs coincide with accumulation of DCs 
in mBSA arthritis, but expression of survivin in DC do not determine 
whether the T cell response to mBSA is tolerogenic or immunogenic. 
• Flt3 inhibition with sunitinib decreases the frequency of DCs and the 
priming against mBSA when administered at immunisation. 
• Intracellular survivin boost the arthritogenic properties of fibroblasts. 
Figure 19. This figure summaries the main findings in the thesis. Flt3L is 
expressed within the arthritic joint. Flt3 signalling in hematopoietic progenitors 
will lead to the up-regulation of survivin and differentiation into DCs. DCs will 
accumulate in secondary lymphoid organs, due to differentiation or clonal 
expansion. Flt3L also enhances DC migration into the joint, where survivin 
expression is further enhanced by contact with the RA-FLS expressing 
membrane bound Flt3L. This will potentially enhance local presentation of 
autoantigens to T cells. Activated RA-FLS express survivin and release uPA. 
uPAR is expressed by both RA-FLS and and monocytes in the RA joint. 
Expression of uPAR that can bind uPA will lead to further up-regulation of 
survivin. Monocytes activated by uPA express IL-8 that will lead to neutrophil 
recruitment.  
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